Literature DB >> 34697200

Malignant Struma Ovarii Τreated With Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Miklos Acs1, Sebastian Häusler2, Hamid-Reza Lighvani3, Jozef Zustin4,5, Pompiliu Piso6.   

Abstract

BACKGROUND/AIM: Malignant struma ovarii is an extremely rare tumor entity among ovarian tumors. In the presence of ascites and peritoneal metastases, the preoperative appearance may resemble the most common epithelial ovarian carcinoma (EOC) and accordingly, the surgical therapy may be identical if a preoperative histology diagnosis is not possible. The objective of this case report is to present a patient with histopathologically confirmed malignant struma ovarii who underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS and HIPEC) with the aim of complete tumor resection. CASE REPORT: This study reports on a patient with preoperatively proven peritoneal metastasis of an 18 cm ovarian tumor with large struma ovarii and papillary thyroid carcinoma within the struma, who was treated with CRS and HIPEC after neoadjuvant chemotherapy.
CONCLUSION: This disease has a significantly better prognosis than EOC, however, HIPEC could provide an additional effect in examining the presence of peritoneal metastasis.
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  HIPEC; Malignant struma ovarii; ovarian cancer; peritoneal carcinosis

Mesh:

Year:  2021        PMID: 34697200      PMCID: PMC8627771          DOI: 10.21873/invivo.12664

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  26 in total

1.  Functioning liver metastases on an I-131 whole-body scan: a case of malignant struma ovarii.

Authors:  O Konez; L G Hanelin; E L Jenison; M Goyal; W Randolph
Journal:  Clin Nucl Med       Date:  2000-06       Impact factor: 7.794

2.  Papillary thyroid microcarcinoma in struma ovarii.

Authors:  Domenico Meringolo; Davide Bianchi; Carmelo Capula; Giuseppe Costante
Journal:  Endocrine       Date:  2012-02       Impact factor: 3.633

Review 3.  Thyroid-type carcinoma of struma ovarii.

Authors:  Xuchen Zhang; Constantine Axiotis
Journal:  Arch Pathol Lab Med       Date:  2010-05       Impact factor: 5.534

4.  Cancer in Malmö 1958-1969. An autopsy study.

Authors:  T Berge; S Lundberg
Journal:  Acta Pathol Microbiol Scand Suppl       Date:  1977

5.  The lack of consensus in management of malignant struma ovarii.

Authors:  Beatriz González Aguilera; Raquel Guerrero Vázquez; Noelia Gros Herguido; Felicia Sánchez Gallego; Elena Navarro González
Journal:  Gynecol Endocrinol       Date:  2014-12-24       Impact factor: 2.260

6.  Natural history of biologically malignant struma ovarii: analysis of 27 cases with extraovarian spread.

Authors:  Ruthy Shaco-Levy; Sarah M Bean; Rex C Bentley; Stanley J Robboy
Journal:  Int J Gynecol Pathol       Date:  2010-05       Impact factor: 2.762

Review 7.  Malignant struma ovarii: a case report and analysis of cases reported in the literature with focus on survival and I131 therapy.

Authors:  Christopher P DeSimone; Subodh M Lele; Susan C Modesitt
Journal:  Gynecol Oncol       Date:  2003-06       Impact factor: 5.482

8.  Extensive peritoneal implant metastases of malignant struma ovarii treated by thyroidectomy and 131I therapy: A case report.

Authors:  Mengxue Wu; Fengqiong Hu; Xing Huang; Zuwen Tan; Chengming Lei; Dong Duan
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.889

9.  Clinical characteristics and survival outcomes of malignant struma ovarii confined to the ovary.

Authors:  Sijian Li; Tengyu Yang; Yang Xiang; Xiaoyan Li; Limeng Zhang; Shan Deng
Journal:  BMC Cancer       Date:  2021-04-09       Impact factor: 4.430

Review 10.  Papillary thyroid cancer located in malignant struma ovarii with omentum metastasis: a case report and review of the literature.

Authors:  Yi Zhu; Chang Wang; Guo-Nan Zhang; Yu Shi; Shi-Qiang Xu; Shi-Jun Jia; Rong He
Journal:  World J Surg Oncol       Date:  2016-01-20       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.